Ahmed Elkhanany

Assistant Professor

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Ahmed Elkhanany is an Assistant Professor at the UAB Comprehensive Cancer Center in the United States. His research primarily focuses on breast cancer, including therapeutic clinical trial disparities, the genetic underpinnings of advanced-stage carcinomas, and the role of the tumor microenvironment. Recent publications highlight his work on treatment efficacy, including studies involving hormonal therapies and immune cell contributions to cancer progression.

Articles (11)

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

UNITED STATES

View details

Christos Vaklavas

University of Utah

UNITED STATES

View details

Cristina Magi‐Galluzzi

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ahmed Elkhanany

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Therapeutic Clinical Trial Eligibility and Enrollment among Women with Breast Cancer: Implications for Understanding Trial Disparities

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model

Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma

Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2

Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer

Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion

Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021

Contribution of immune cells to glucocorticoid receptor expression in breast cancer

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020

Collaborators (9)

Mathew Cherian

Song Yao

Mateusz Opyrchal

Nusrat Jahan

Gabrielle Rocque

Hemn Mohammadpour

Shuko Harada

Christos Vaklavas

Cristina Magi‐Galluzzi

Make your next move.